{"transactions":[{"id":2895,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2036,"kind":"person","name":"McCourt Marion","position":1,"cik":"0001663758","reported_name":"McCourt Marion","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Commercial"}}],"security":"Common Stock","published_at":"2026-09-03T20:50:59.000Z","date":"2026-09-03","kind":"sale","planned":true,"acquired":false,"shares":1131,"price":857.39,"value":969708.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026."}],"balance_after":12003,"source":{"system":"sec-edgar","filing":"0001663758-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1663758/000166375826000002/edgardoc.xml","form_type":"4"}},{"id":2894,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2036,"kind":"person","name":"McCourt Marion","position":1,"cik":"0001663758","reported_name":"McCourt Marion","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Commercial"}}],"security":"Common Stock","published_at":"2026-09-03T20:50:59.000Z","date":"2026-09-02","kind":"sale","planned":true,"acquired":false,"shares":1215,"price":850,"value":1032750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026."}],"balance_after":13134,"source":{"system":"sec-edgar","filing":"0001663758-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1663758/000166375826000002/edgardoc.xml","form_type":"4"}},{"id":2804,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2011,"kind":"person","name":"Guarini Kathryn","position":1,"cik":"0001992352","reported_name":"Guarini Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-09-03T20:47:22.000Z","date":"2026-09-02","kind":"exercise","planned":true,"acquired":false,"shares":400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant."}],"balance_after":1158,"derivative":{"exercise_price":719.37,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001992352-26-000007","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1992352/000199235226000007/edgardoc.xml","form_type":"4"}},{"id":2803,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2011,"kind":"person","name":"Guarini Kathryn","position":1,"cik":"0001992352","reported_name":"Guarini Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-03T20:47:22.000Z","date":"2026-09-02","kind":"sale","planned":true,"acquired":false,"shares":400,"price":850,"value":340000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026."}],"balance_after":603,"source":{"system":"sec-edgar","filing":"0001992352-26-000007","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1992352/000199235226000007/edgardoc.xml","form_type":"4"}},{"id":2802,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2011,"kind":"person","name":"Guarini Kathryn","position":1,"cik":"0001992352","reported_name":"Guarini Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-03T20:47:22.000Z","date":"2026-09-02","kind":"exercise","planned":true,"acquired":true,"shares":400,"price":719.37,"value":287748.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026."}],"balance_after":1003,"source":{"system":"sec-edgar","filing":"0001992352-26-000007","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1992352/000199235226000007/edgardoc.xml","form_type":"4"}},{"id":679346,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":14140,"kind":"person","name":"LAROSA JOSEPH J","position":1,"cik":"0001238303","reported_name":"LAROSA JOSEPH J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel and Secret"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-08-21T20:01:23.000Z","date":"2026-08-19","kind":"exercise","planned":false,"acquired":false,"shares":12282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award vested in four equal annual installments, commencing one year after the date of grant."}],"balance_after":12283,"derivative":{"exercise_price":381.92,"expiration_date":"2026-12-16","underlying":"Common Stock","underlying_shares":12282},"source":{"system":"sec-edgar","filing":"0001238303-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000123830326000002/edgardoc.xml","form_type":"4"}},{"id":679345,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":14140,"kind":"person","name":"LAROSA JOSEPH J","position":1,"cik":"0001238303","reported_name":"LAROSA JOSEPH J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel and Secret"}}],"security":"Common Stock","published_at":"2026-08-21T20:01:23.000Z","date":"2026-08-19","kind":"tax_withholding","planned":false,"acquired":false,"shares":9019,"price":830.15,"value":7487122.85,"ownership":{"direct":true},"balance_after":36373,"source":{"system":"sec-edgar","filing":"0001238303-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000123830326000002/edgardoc.xml","form_type":"4"}},{"id":679344,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":14140,"kind":"person","name":"LAROSA JOSEPH J","position":1,"cik":"0001238303","reported_name":"LAROSA JOSEPH J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP General Counsel and Secret"}}],"security":"Common Stock","published_at":"2026-08-21T20:01:23.000Z","date":"2026-08-19","kind":"exercise","planned":false,"acquired":true,"shares":12282,"price":381.92,"value":4690741.44,"ownership":{"direct":true},"balance_after":45392,"source":{"system":"sec-edgar","filing":"0001238303-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000123830326000002/edgardoc.xml","form_type":"4"}},{"id":680561,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":21402,"kind":"person","name":"Fenimore Christopher R.","position":1,"cik":"0001697422","reported_name":"Fenimore Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-08-20T20:01:28.000Z","date":"2026-08-18","kind":"exercise","planned":false,"acquired":false,"shares":6283,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award vested in four equal annual installments, commencing one year after the date of grant."}],"balance_after":6000,"derivative":{"exercise_price":381.92,"expiration_date":"2026-12-16","underlying":"Common Stock","underlying_shares":6283},"source":{"system":"sec-edgar","filing":"0001697422-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000169742226000002/edgardoc.xml","form_type":"4"}},{"id":680560,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":21402,"kind":"person","name":"Fenimore Christopher R.","position":1,"cik":"0001697422","reported_name":"Fenimore Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2026-08-20T20:01:28.000Z","date":"2026-08-18","kind":"tax_withholding","planned":false,"acquired":false,"shares":4599,"price":813.47,"value":3741148.53,"ownership":{"direct":true},"balance_after":19984,"source":{"system":"sec-edgar","filing":"0001697422-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000169742226000002/edgardoc.xml","form_type":"4"}},{"id":680559,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":21402,"kind":"person","name":"Fenimore Christopher R.","position":1,"cik":"0001697422","reported_name":"Fenimore Christopher R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Finance CFO"}}],"security":"Common Stock","published_at":"2026-08-20T20:01:28.000Z","date":"2026-08-18","kind":"exercise","planned":false,"acquired":true,"shares":6283,"price":381.92,"value":2399603.36,"ownership":{"direct":true},"balance_after":24583,"source":{"system":"sec-edgar","filing":"0001697422-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000169742226000002/edgardoc.xml","form_type":"4"}},{"id":689930,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2011,"kind":"person","name":"Guarini Kathryn","position":1,"cik":"0001992352","reported_name":"Guarini Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-08-12T20:16:51.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":false,"shares":400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant."}],"balance_after":1558,"derivative":{"exercise_price":719.37,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001992352-26-000005","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000199235226000005/edgardoc.xml","form_type":"4"}},{"id":689929,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2011,"kind":"person","name":"Guarini Kathryn","position":1,"cik":"0001992352","reported_name":"Guarini Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-12T20:16:51.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":400,"price":800,"value":320000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026."}],"balance_after":603,"source":{"system":"sec-edgar","filing":"0001992352-26-000005","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000199235226000005/edgardoc.xml","form_type":"4"}},{"id":689928,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2011,"kind":"person","name":"Guarini Kathryn","position":1,"cik":"0001992352","reported_name":"Guarini Kathryn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-12T20:16:51.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":true,"shares":400,"price":719.37,"value":287748.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026."}],"balance_after":1003,"source":{"system":"sec-edgar","filing":"0001992352-26-000005","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000199235226000005/edgardoc.xml","form_type":"4"}},{"id":689927,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":24351,"kind":"person","name":"Zoghbi Huda Y","position":1,"cik":"0001681643","reported_name":"Zoghbi Huda Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-08-12T20:14:48.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":false,"shares":800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vested in three equal annual installments, commencing one year after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":376.69,"expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":800},"source":{"system":"sec-edgar","filing":"0001681643-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168164326000006/edgardoc.xml","form_type":"4"}},{"id":689926,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":24351,"kind":"person","name":"Zoghbi Huda Y","position":1,"cik":"0001681643","reported_name":"Zoghbi Huda Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-12T20:14:48.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":800,"price":800,"value":640000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025."}],"balance_after":1703,"source":{"system":"sec-edgar","filing":"0001681643-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168164326000006/edgardoc.xml","form_type":"4"}},{"id":689925,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":24351,"kind":"person","name":"Zoghbi Huda Y","position":1,"cik":"0001681643","reported_name":"Zoghbi Huda Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-12T20:14:48.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":true,"shares":800,"price":376.69,"value":301352.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025."}],"balance_after":2503,"source":{"system":"sec-edgar","filing":"0001681643-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168164326000006/edgardoc.xml","form_type":"4"}},{"id":714048,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T20:05:04.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":200,"price":650.15,"value":130030.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price."}],"balance_after":17303,"source":{"system":"sec-edgar","filing":"0001187443-26-000010","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000010/edgardoc.xml","form_type":"4"}},{"id":794599,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":2,"price":714.13,"value":1428.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents volume-weighted average price of sales of 2 shares of Company stock on May 1, 2026 at prices ranging from $714.12 to $714.14. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price."}],"balance_after":17503,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":794598,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":1,"price":712.09,"value":712.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."}],"balance_after":17505,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":794597,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":5,"price":711.49,"value":3557.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents volume-weighted average price of sales of 5 shares of Company stock on May 1, 2026 at prices ranging from $711.17 to $711.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price."}],"balance_after":17506,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":794596,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":2,"price":710.87,"value":1421.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents volume-weighted average price of sales of 2 shares of Company stock on May 1, 2026 at prices ranging from $710.86 to $710.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price."}],"balance_after":17511,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":794595,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":6,"price":709.45,"value":4256.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents volume-weighted average price of sales of 6 shares of Company stock on May 1, 2026 at prices ranging from $709.05 to $709.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price."}],"balance_after":17513,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":794594,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":4,"price":707.4,"value":2829.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 4 shares of Company stock on May 1, 2026 at prices ranging from $707.12 to $707.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price."}],"balance_after":17519,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":794593,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":7,"price":706.74,"value":4947.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 7 shares of Company stock on May 1, 2026 at prices ranging from $706.05 to $706.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price."}],"balance_after":17523,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":794592,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":14,"price":705.56,"value":9877.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 14 shares of Company stock on May 1, 2026 at prices ranging from $705.02 to $705.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price."}],"balance_after":17530,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":794591,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":15,"price":704.28,"value":10564.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 15 shares of Company stock on May 1, 2026 at prices ranging from $704.01 to $704.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price."}],"balance_after":17544,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":794590,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":24,"price":703.46,"value":16883.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 24 shares of Company stock on May 1, 2026 at prices ranging from $703.01 to $703.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price."}],"balance_after":17559,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":794589,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":15,"price":702.46,"value":10536.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 15 shares of Company stock on May 1, 2026 at prices ranging from $702.02 to $702.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price."}],"balance_after":17583,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":794588,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:14:55.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":5,"price":701.76,"value":3508.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 5 shares of Company stock on May 1, 2026 at prices ranging from $701.36 to $701.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price."}],"balance_after":17598,"source":{"system":"sec-edgar","filing":"0001187443-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000008/edgardoc.xml","form_type":"4"}},{"id":817910,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T20:01:09.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":40,"price":779.71,"value":31188.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents volume-weighted average price of sales of 40 shares of Company stock on April 1, 2026 at prices ranging from $779.65 to $779.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price."}],"balance_after":17603,"source":{"system":"sec-edgar","filing":"0001104659-26-039613","document":"tm2611142-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926039613/tm2611142-1_4seq1.xml","form_type":"4"}},{"id":817909,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T20:01:09.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":4,"price":778.24,"value":3112.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 4 shares of Company stock on April 1, 2026 at prices ranging from $778.02 to $778.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price."}],"balance_after":17643,"source":{"system":"sec-edgar","filing":"0001104659-26-039613","document":"tm2611142-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926039613/tm2611142-1_4seq1.xml","form_type":"4"}},{"id":817908,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T20:01:09.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":9,"price":777.42,"value":6996.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 9 shares of Company stock on April 1, 2026 at prices ranging from $777.03 to $777.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price."}],"balance_after":17647,"source":{"system":"sec-edgar","filing":"0001104659-26-039613","document":"tm2611142-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926039613/tm2611142-1_4seq1.xml","form_type":"4"}},{"id":817907,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T20:01:09.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":13,"price":776.62,"value":10096.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 13 shares of Company stock on April 1, 2026 at prices ranging from $776.11 to $776.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price."}],"balance_after":17656,"source":{"system":"sec-edgar","filing":"0001104659-26-039613","document":"tm2611142-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926039613/tm2611142-1_4seq1.xml","form_type":"4"}},{"id":817906,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T20:01:09.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":14,"price":775.58,"value":10858.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 14 shares of Company stock on April 1, 2026 at prices ranging from $775.04 to $775.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price."}],"balance_after":17669,"source":{"system":"sec-edgar","filing":"0001104659-26-039613","document":"tm2611142-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926039613/tm2611142-1_4seq1.xml","form_type":"4"}},{"id":817905,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T20:01:09.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":8,"price":774.58,"value":6196.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 8 shares of Company stock on April 1, 2026 at prices ranging from $774.05 to $774.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price."}],"balance_after":17683,"source":{"system":"sec-edgar","filing":"0001104659-26-039613","document":"tm2611142-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926039613/tm2611142-1_4seq1.xml","form_type":"4"}},{"id":817904,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T20:01:09.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":8,"price":773.59,"value":6188.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 8 shares of Company stock on April 1, 2026 at prices ranging from $773.27 to $773.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price."}],"balance_after":17691,"source":{"system":"sec-edgar","filing":"0001104659-26-039613","document":"tm2611142-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926039613/tm2611142-1_4seq1.xml","form_type":"4"}},{"id":817903,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T20:01:09.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":3,"price":772.76,"value":2318.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 3 shares of Company stock on April 1, 2026 at prices ranging from $772.62 to $772.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price."}],"balance_after":17699,"source":{"system":"sec-edgar","filing":"0001104659-26-039613","document":"tm2611142-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926039613/tm2611142-1_4seq1.xml","form_type":"4"}},{"id":817902,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T20:01:09.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":1,"price":771.32,"value":771.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."}],"balance_after":17702,"source":{"system":"sec-edgar","filing":"0001104659-26-039613","document":"tm2611142-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926039613/tm2611142-1_4seq1.xml","form_type":"4"}},{"id":871319,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":20,"price":789.28,"value":15785.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Represents volume-weighted average price of sales of 20 shares of Company stock on March 2, 2026 at prices ranging from $789.27 to $789.37. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17703,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871318,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":20,"price":788.96,"value":15779.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."}],"balance_after":17723,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871317,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":2,"price":787.34,"value":1574.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $787.02 to $787.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17743,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871316,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":7,"price":786.61,"value":5506.27,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents volume-weighted average price of sales of 7 shares of Company stock on March 2, 2026 at prices ranging from $786.12 to $786.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17745,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871315,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":11,"price":785.48,"value":8640.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents volume-weighted average price of sales of 11 shares of Company stock on March 2, 2026 at prices ranging from $785.02 to $785.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17752,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871314,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":9,"price":784.48,"value":7060.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents volume-weighted average price of sales of 9 shares of Company stock on March 2, 2026 at prices ranging from $784.02 to $784.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17763,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871313,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":10,"price":783.62,"value":7836.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 10 shares of Company stock on March 2, 2026 at prices ranging from $783.25 to $783.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17772,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871312,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":2,"price":782.62,"value":1565.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $782.25 to $782.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17782,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871311,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":2,"price":781.21,"value":1562.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $781.00 to $781.42. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17784,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871310,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":3,"price":780.69,"value":2342.07,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 3 shares of Company stock on March 2, 2026 at prices ranging from $780.13 to $780.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17786,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871309,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":5,"price":779.69,"value":3898.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 5 shares of Company stock on March 2, 2026 at prices ranging from $779.36 to $779.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17789,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871308,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":2,"price":778.3,"value":1556.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $778.27 to $778.33. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17794,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":871307,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:01:53.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":7,"price":777.46,"value":5442.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 7 shares of Company stock on March 2, 2026 at prices ranging from $777.08 to $777.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price."}],"balance_after":17796,"source":{"system":"sec-edgar","filing":"0001187443-26-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000006/edgardoc.xml","form_type":"4"}},{"id":889170,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":24351,"kind":"person","name":"Zoghbi Huda Y","position":1,"cik":"0001681643","reported_name":"Zoghbi Huda Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-02-23T21:55:58.000Z","date":"2026-02-19","kind":"exercise","planned":true,"acquired":false,"shares":1638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The stock option vested in three equal annual installments, commencing one year after the date of grant."}],"balance_after":800,"derivative":{"exercise_price":376.69,"expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":1638},"source":{"system":"sec-edgar","filing":"0001681643-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168164326000004/edgardoc.xml","form_type":"4"}},{"id":889169,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":24351,"kind":"person","name":"Zoghbi Huda Y","position":1,"cik":"0001681643","reported_name":"Zoghbi Huda Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-23T21:55:58.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":4,"price":790,"value":3160.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025."}],"balance_after":1703,"source":{"system":"sec-edgar","filing":"0001681643-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168164326000004/edgardoc.xml","form_type":"4"}},{"id":889168,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":24351,"kind":"person","name":"Zoghbi Huda Y","position":1,"cik":"0001681643","reported_name":"Zoghbi Huda Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-23T21:55:58.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":56,"price":785.61,"value":43994.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents volume-weighted average price of sales of 56 shares of Company stock on February 19, 2026 at prices ranging from $785.60 to $785.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price."}],"balance_after":1707,"source":{"system":"sec-edgar","filing":"0001681643-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168164326000004/edgardoc.xml","form_type":"4"}},{"id":889167,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":24351,"kind":"person","name":"Zoghbi Huda Y","position":1,"cik":"0001681643","reported_name":"Zoghbi Huda Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-23T21:55:58.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":160,"price":784.45,"value":125512.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 160 shares of Company stock on February 19, 2026 at prices ranging from $784.14 to $784.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price."}],"balance_after":1763,"source":{"system":"sec-edgar","filing":"0001681643-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168164326000004/edgardoc.xml","form_type":"4"}},{"id":889166,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":24351,"kind":"person","name":"Zoghbi Huda Y","position":1,"cik":"0001681643","reported_name":"Zoghbi Huda Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-23T21:55:58.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":220,"price":783.29,"value":172323.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 220 shares of Company stock on February 19, 2026 at prices ranging from $783.00 to $783.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price."}],"balance_after":1923,"source":{"system":"sec-edgar","filing":"0001681643-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168164326000004/edgardoc.xml","form_type":"4"}},{"id":889165,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":24351,"kind":"person","name":"Zoghbi Huda Y","position":1,"cik":"0001681643","reported_name":"Zoghbi Huda Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-23T21:55:58.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":298,"price":782.1,"value":233065.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 298 shares of Company stock on February 19, 2026 at prices ranging from $782.01 to $782.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price."}],"balance_after":2143,"source":{"system":"sec-edgar","filing":"0001681643-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168164326000004/edgardoc.xml","form_type":"4"}},{"id":889164,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":24351,"kind":"person","name":"Zoghbi Huda Y","position":1,"cik":"0001681643","reported_name":"Zoghbi Huda Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-23T21:55:58.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":209,"price":781.28,"value":163287.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 209 shares of Company stock on February 19, 2026 at prices ranging from $781.10 to $781.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price."}],"balance_after":2441,"source":{"system":"sec-edgar","filing":"0001681643-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168164326000004/edgardoc.xml","form_type":"4"}},{"id":889163,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":24351,"kind":"person","name":"Zoghbi Huda Y","position":1,"cik":"0001681643","reported_name":"Zoghbi Huda Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-23T21:55:58.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":331,"price":780.45,"value":258328.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 331 shares of Company stock on February 19, 2026 at prices ranging from $780.06 to $780.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price."}],"balance_after":2650,"source":{"system":"sec-edgar","filing":"0001681643-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168164326000004/edgardoc.xml","form_type":"4"}},{"id":889162,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":24351,"kind":"person","name":"Zoghbi Huda Y","position":1,"cik":"0001681643","reported_name":"Zoghbi Huda Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-23T21:55:58.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":208,"price":779.55,"value":162146.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 208 shares of Company stock on February 19, 2026 at prices ranging from $779.10 to $779.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price."}],"balance_after":2981,"source":{"system":"sec-edgar","filing":"0001681643-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168164326000004/edgardoc.xml","form_type":"4"}},{"id":889161,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":24351,"kind":"person","name":"Zoghbi Huda Y","position":1,"cik":"0001681643","reported_name":"Zoghbi Huda Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-23T21:55:58.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":53,"price":778.47,"value":41258.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 53 shares of Company stock on February 19, 2026 at prices ranging from $778.46 to $778.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price."}],"balance_after":3189,"source":{"system":"sec-edgar","filing":"0001681643-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168164326000004/edgardoc.xml","form_type":"4"}},{"id":889160,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":24351,"kind":"person","name":"Zoghbi Huda Y","position":1,"cik":"0001681643","reported_name":"Zoghbi Huda Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-23T21:55:58.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":50,"price":775.5,"value":38775.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025."}],"balance_after":3242,"source":{"system":"sec-edgar","filing":"0001681643-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168164326000004/edgardoc.xml","form_type":"4"}},{"id":889159,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":24351,"kind":"person","name":"Zoghbi Huda Y","position":1,"cik":"0001681643","reported_name":"Zoghbi Huda Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-23T21:55:58.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":49,"price":774.68,"value":37959.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025."}],"balance_after":3292,"source":{"system":"sec-edgar","filing":"0001681643-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168164326000004/edgardoc.xml","form_type":"4"}},{"id":889158,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":24351,"kind":"person","name":"Zoghbi Huda Y","position":1,"cik":"0001681643","reported_name":"Zoghbi Huda Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-23T21:55:58.000Z","date":"2026-02-19","kind":"exercise","planned":true,"acquired":true,"shares":1638,"price":376.69,"value":617018.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025."}],"balance_after":3341,"source":{"system":"sec-edgar","filing":"0001681643-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168164326000004/edgardoc.xml","form_type":"4"}},{"id":910742,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":66935,"kind":"person","name":"Pitofsky Jason","position":1,"cik":"0002009236","reported_name":"Pitofsky Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Controller"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-02-11T21:03:58.000Z","date":"2026-02-09","kind":"exercise","planned":true,"acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The stock option award vested in four equal annual installments, commencing one year after the date of grant."}],"balance_after":905,"derivative":{"exercise_price":492,"expiration_date":"2030-12-09","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0002009236-26-000001","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/872589/000200923626000001/edgardoc.xml","form_type":"4"}},{"id":910741,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":66935,"kind":"person","name":"Pitofsky Jason","position":1,"cik":"0002009236","reported_name":"Pitofsky Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Controller"}}],"security":"Common Stock","published_at":"2026-02-11T21:03:58.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":53,"price":785.72,"value":41643.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents volume-weighted average price of sales of 53 shares of Company stock on February 9, 2026 at prices ranging from $785.72 to $785.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price."}],"balance_after":4272,"source":{"system":"sec-edgar","filing":"0002009236-26-000001","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000200923626000001/edgardoc.xml","form_type":"4"}},{"id":910740,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":66935,"kind":"person","name":"Pitofsky Jason","position":1,"cik":"0002009236","reported_name":"Pitofsky Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Controller"}}],"security":"Common Stock","published_at":"2026-02-11T21:03:58.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":1,"price":784.66,"value":784.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025."}],"balance_after":4325,"source":{"system":"sec-edgar","filing":"0002009236-26-000001","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000200923626000001/edgardoc.xml","form_type":"4"}},{"id":910739,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":66935,"kind":"person","name":"Pitofsky Jason","position":1,"cik":"0002009236","reported_name":"Pitofsky Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Controller"}}],"security":"Common Stock","published_at":"2026-02-11T21:03:58.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":144,"price":783.23,"value":112785.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents volume-weighted average price of sales of 144 shares of Company stock on February 9, 2026 at prices ranging from $783.17 to $783.29. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price."}],"balance_after":4326,"source":{"system":"sec-edgar","filing":"0002009236-26-000001","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000200923626000001/edgardoc.xml","form_type":"4"}},{"id":910738,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":66935,"kind":"person","name":"Pitofsky Jason","position":1,"cik":"0002009236","reported_name":"Pitofsky Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Controller"}}],"security":"Common Stock","published_at":"2026-02-11T21:03:58.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":37,"price":782.67,"value":28958.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 37 shares of Company stock on February 9, 2026 at prices ranging from $782.22 to $782.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price."}],"balance_after":4470,"source":{"system":"sec-edgar","filing":"0002009236-26-000001","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000200923626000001/edgardoc.xml","form_type":"4"}},{"id":910737,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":66935,"kind":"person","name":"Pitofsky Jason","position":1,"cik":"0002009236","reported_name":"Pitofsky Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Controller"}}],"security":"Common Stock","published_at":"2026-02-11T21:03:58.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":26,"price":781.37,"value":20315.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 26 shares of Company stock on February 9, 2026 at prices ranging from $781.18 to $781.53. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price."}],"balance_after":4507,"source":{"system":"sec-edgar","filing":"0002009236-26-000001","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000200923626000001/edgardoc.xml","form_type":"4"}},{"id":910736,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":66935,"kind":"person","name":"Pitofsky Jason","position":1,"cik":"0002009236","reported_name":"Pitofsky Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Controller"}}],"security":"Common Stock","published_at":"2026-02-11T21:03:58.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":75,"price":780.06,"value":58504.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 75 shares of Company stock on February 9, 2026 at prices ranging from $780.03 to $780.65. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price."}],"balance_after":4533,"source":{"system":"sec-edgar","filing":"0002009236-26-000001","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000200923626000001/edgardoc.xml","form_type":"4"}},{"id":910735,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":66935,"kind":"person","name":"Pitofsky Jason","position":1,"cik":"0002009236","reported_name":"Pitofsky Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Controller"}}],"security":"Common Stock","published_at":"2026-02-11T21:03:58.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":205,"price":779.56,"value":159809.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 205 shares of Company stock on February 9, 2026 at prices ranging from $779.19 to $779.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price."}],"balance_after":4608,"source":{"system":"sec-edgar","filing":"0002009236-26-000001","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000200923626000001/edgardoc.xml","form_type":"4"}},{"id":910734,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":66935,"kind":"person","name":"Pitofsky Jason","position":1,"cik":"0002009236","reported_name":"Pitofsky Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Controller"}}],"security":"Common Stock","published_at":"2026-02-11T21:03:58.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":563,"price":778.35,"value":438211.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 563 shares of Company stock on February 9, 2026 at prices ranging from $778.00 to $778.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price."}],"balance_after":4813,"source":{"system":"sec-edgar","filing":"0002009236-26-000001","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000200923626000001/edgardoc.xml","form_type":"4"}},{"id":910733,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":66935,"kind":"person","name":"Pitofsky Jason","position":1,"cik":"0002009236","reported_name":"Pitofsky Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Controller"}}],"security":"Common Stock","published_at":"2026-02-11T21:03:58.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":391,"price":777.51,"value":304006.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 391 shares of Company stock on February 9, 2026 at prices ranging from $777.33 to $777.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price."}],"balance_after":5376,"source":{"system":"sec-edgar","filing":"0002009236-26-000001","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000200923626000001/edgardoc.xml","form_type":"4"}},{"id":910732,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":66935,"kind":"person","name":"Pitofsky Jason","position":1,"cik":"0002009236","reported_name":"Pitofsky Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Controller"}}],"security":"Common Stock","published_at":"2026-02-11T21:03:58.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":521,"price":776.43,"value":404520.03,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 521 shares of Company stock on February 9, 2026 at prices ranging from $776.05 to $776.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price."}],"balance_after":5767,"source":{"system":"sec-edgar","filing":"0002009236-26-000001","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000200923626000001/edgardoc.xml","form_type":"4"}},{"id":910731,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":66935,"kind":"person","name":"Pitofsky Jason","position":1,"cik":"0002009236","reported_name":"Pitofsky Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Controller"}}],"security":"Common Stock","published_at":"2026-02-11T21:03:58.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":20,"price":775.95,"value":15519.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025."}],"balance_after":6288,"source":{"system":"sec-edgar","filing":"0002009236-26-000001","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000200923626000001/edgardoc.xml","form_type":"4"}},{"id":910730,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":66935,"kind":"person","name":"Pitofsky Jason","position":1,"cik":"0002009236","reported_name":"Pitofsky Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Controller"}}],"security":"Common Stock","published_at":"2026-02-11T21:03:58.000Z","date":"2026-02-09","kind":"exercise","planned":true,"acquired":true,"shares":1000,"price":492,"value":492000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025."}],"balance_after":6308,"source":{"system":"sec-edgar","filing":"0002009236-26-000001","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000200923626000001/edgardoc.xml","form_type":"4"}},{"id":910729,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":1,"price":787.82,"value":787.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."}],"balance_after":17803,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910728,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":2,"price":786.29,"value":1572.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."}],"balance_after":17804,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910727,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":1,"price":785.71,"value":785.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."}],"balance_after":17806,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910726,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":1,"price":784.59,"value":784.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."}],"balance_after":17807,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910725,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":3,"price":783.34,"value":2350.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 3 shares of Company stock on February 9, 2026 at prices ranging from $783.20 to $783.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price."}],"balance_after":17808,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910724,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":1,"price":782.53,"value":782.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."}],"balance_after":17811,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910723,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":5,"price":781.48,"value":3907.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 5 shares of Company stock on February 9, 2026 at prices ranging from $781.05 to $781.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price."}],"balance_after":17812,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910722,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":1,"price":780.09,"value":780.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."}],"balance_after":17817,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910721,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":5,"price":779.41,"value":3897.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 5 shares of Company stock on February 9, 2026 at prices ranging from $779.13 to $779.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price."}],"balance_after":17818,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910720,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":12,"price":778.53,"value":9342.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 12 shares of Company stock on February 9, 2026 at prices ranging from $778.11 to $778.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price."}],"balance_after":17823,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910719,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":57,"price":777.56,"value":44320.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 57 shares of Company stock on February 9, 2026 at prices ranging from $777.02 to $777.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price."}],"balance_after":17835,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910718,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":10,"price":776.59,"value":7765.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 10 shares of Company stock on February 9, 2026 at prices ranging from $776.04 to $776.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price."}],"balance_after":17892,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":910717,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":31856,"kind":"person","name":"RYAN ARTHUR F","position":1,"cik":"0001187443","reported_name":"RYAN ARTHUR F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:02:23.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":1,"price":775.63,"value":775.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025."}],"balance_after":17902,"source":{"system":"sec-edgar","filing":"0001187443-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000118744326000004/edgardoc.xml","form_type":"4"}},{"id":943671,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-01-08T21:03:19.000Z","date":"2026-01-07","kind":"exercise","planned":true,"acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant."}],"balance_after":2861,"derivative":{"exercise_price":374.12,"expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001683607-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168360726000008/edgardoc.xml","form_type":"4"}},{"id":943670,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-08T21:03:19.000Z","date":"2026-01-07","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":800,"value":1200000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 1,500 shares of Company stock on January 7, 2026 at prices ranging from $800.00 to $800.01. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 7, 2026 at each separate price."}],"balance_after":1703,"source":{"system":"sec-edgar","filing":"0001683607-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168360726000008/edgardoc.xml","form_type":"4"}},{"id":943669,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-08T21:03:19.000Z","date":"2026-01-07","kind":"exercise","planned":true,"acquired":true,"shares":1500,"price":374.12,"value":561180.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025."}],"balance_after":3203,"source":{"system":"sec-edgar","filing":"0001683607-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168360726000008/edgardoc.xml","form_type":"4"}},{"id":948763,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":24351,"kind":"person","name":"Zoghbi Huda Y","position":1,"cik":"0001681643","reported_name":"Zoghbi Huda Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-01-06T21:21:24.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":1962,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant."}],"balance_after":1962,"derivative":{"exercise_price":772.76,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":1962},"source":{"system":"sec-edgar","filing":"0001681643-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168164326000002/edgardoc.xml","form_type":"4"}},{"id":948762,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":24351,"kind":"person","name":"Zoghbi Huda Y","position":1,"cik":"0001681643","reported_name":"Zoghbi Huda Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T21:21:24.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":155,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock."}],"balance_after":1703,"source":{"system":"sec-edgar","filing":"0001681643-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168164326000002/edgardoc.xml","form_type":"4"}},{"id":948761,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":12116,"kind":"person","name":"Thompson Craig B.","position":1,"cik":"0001423419","reported_name":"Thompson Craig B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-01-06T21:18:21.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":1962,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant."}],"balance_after":1962,"derivative":{"exercise_price":772.76,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":1962},"source":{"system":"sec-edgar","filing":"0001423419-26-000001","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000142341926000001/edgardoc.xml","form_type":"4"}},{"id":948760,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":12116,"kind":"person","name":"Thompson Craig B.","position":1,"cik":"0001423419","reported_name":"Thompson Craig B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T21:18:21.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":155,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock."}],"balance_after":775,"source":{"system":"sec-edgar","filing":"0001423419-26-000001","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000142341926000001/edgardoc.xml","form_type":"4"}},{"id":948759,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70164,"kind":"person","name":"SING GEORGE L","position":1,"cik":"0001225471","reported_name":"SING GEORGE L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-01-06T21:16:18.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":1962,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant."}],"balance_after":1962,"derivative":{"exercise_price":772.76,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":1962},"source":{"system":"sec-edgar","filing":"0001225471-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000122547126000002/edgardoc.xml","form_type":"4"}},{"id":948758,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":70164,"kind":"person","name":"SING GEORGE L","position":1,"cik":"0001225471","reported_name":"SING GEORGE L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T21:16:18.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":155,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock."}],"balance_after":31007,"source":{"system":"sec-edgar","filing":"0001225471-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000122547126000002/edgardoc.xml","form_type":"4"}}],"next_cursor":"2026-01-06T21:16:18.000000Z,948758"}